Sanofi announces takeover of Ablynx

Sanofi has agreed a deal to acquire Ablynx, a biopharmaceutical company engaged in the discovery and development of nanobody therapies.

The acquisition, which has been valued at EUR 3.9 billion (GBP 3.43 billion), will provide Sanofi with access to a broader portfolio of technologies addressing multiple disease targets with single multi-specific molecules.

Ablynx's flagship nanobody therapies are a novel class of proprietary next-generation biologicals, with the company's deep pipeline including more than 45 proprietary and partnered candidates for therapeutic areas such as haematology, inflammation, immuno-oncology and respiratory diseases.

Eight of these nanobodies have entered clinical development, with Sanofi committed to accelerating development and maximising the commercial potential of these programmes.

Olivier Brandicourt, Sanofi's chief executive officer, said: "With Ablynx, we continue to advance the strategic transformation of our research and development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders."

This comes after the company agreed a deal to purchase Bioverativ earlier this month.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.